The Evaluation of Chinese Therapeutic Food for the Treatment of Moderate Dyslipidemia

الملخص EN

The clinical efficacy of the Chinese therapeutic food (specifically hawthorn fruit and Chinese kiwifruit-extract compound) on dyslipidemia was evaluated in this placebo-controlled, double blind, paired clinical trial conducted in Melbourne, Australia.

Forty-three participants diagnosed with moderate dyslipidemia and met the study criteria were randomly assigned to Group A or B, with baseline characteristics matched.

Twenty-seven participants completed all the tests, the blood lipid profile including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), and triglycerides (TG) was analysed.

The traditional Chinese medicine diagnosis was made based on participants’ symptoms and signs.

The results indicate that a four-week intake of the compound increased the serum HDL-c levels by 5% (P=0.026) and decreased the ratios of TC/HDL-c and LDL-c/HDL-c (P=0.012 and P=0.044, resp.).

The placebo intake did not significantly change the blood lipid profile.

In the initial 43 participants with dyslipidemia, 76.7% of them were diagnosed with “Spleen deficiency” and 58.1% with “Liver qi stagnation.” The intake of hawthorn fruit and Chinese kiwifruit extract compound may increase the serum levels of HDL-c and decrease the ratios of TC/HDL-c and LDL-c/HDL-c, therefore, may reduce the risk of cardiovascular disease.